LifeVantage (NASDAQ:LFVN) updated its FY 2022 earnings guidance on Thursday. The company provided EPS guidance of $0.830-$0.870 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.850. The company issued revenue guidance of $225 million-$235 million, compared to the consensus revenue estimate of $225 million.
Shares of LFVN traded down $0.16 during mid-day trading on Thursday, hitting $7.10. 38,329 shares of the stock were exchanged, compared to its average volume of 96,785. The company has a market cap of $93.98 million, a PE ratio of 7.24 and a beta of 1.35. LifeVantage has a 52-week low of $6.38 and a 52-week high of $11.42. The firm has a 50-day moving average of $6.95 and a two-hundred day moving average of $7.38.
LifeVantage (NASDAQ:LFVN) last released its quarterly earnings results on Thursday, November 4th. The company reported $0.23 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.21 by $0.02. LifeVantage had a net margin of 6.29% and a return on equity of 37.97%. The company had revenue of $53.22 million for the quarter. During the same period in the previous year, the company earned $0.25 EPS. On average, analysts predict that LifeVantage will post 0.85 EPS for the current fiscal year.
LifeVantage Company Profile
LifeVantage Corp. engages in the identification, research, development and distribution of advanced nutraceutical dietary supplements and personal care products. The firm operates through the following geographical segments: Americas Region and Asia/Pacific and Europe Region. Its products include Protandim, LifeVantage Omega+ and ProBio, TrueScience and Petandim for dogs.
Featured Story: What is a Reverse Stock Split?
Receive News & Ratings for LifeVantage Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeVantage and related companies with MarketBeat.com's FREE daily email newsletter.